Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

US Patent 10881648 · Granted Jan 5, 2021

Estimated economic value: $897,227,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for measuring changes in cellular activity in live tissue2025
Ex vivo systems and methods for determining the effect of a drug or other agent 2025
Ex vivo systems and methods for determining the effect of a drug or other agent 2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2024
Combination therapy including a KRASG12C inhibitor and one or more additional ph2024
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Ex vivo systems and methods for determining the effect of a drug or other agent 2022
Ex vivo systems and methods for determining the effect of a drug or other agent 2022
Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof2019